Lupin, Schering Settle Clarinex Patent Dispute; Glenmark, Nycomed Clash Over Cutivate
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Indian drug maker Lupin has settled all its patent litigations with Schering Plough and Sepracor over allergy drug Clarinex (desloratadine). According to the agreement, while the key Clarinex patent expires in 2020, Lupin will gain licenses under the relevant desloratadine patents and will be free to commercially launch its generic desloratadine on July 1, 2012, or earlier in certain circumstances